Business Wire

GSMA: US Gets Set To Clash with Europe at WRC-19

24.10.2019 10:00:00 EEST | Business Wire | Press release

Share

A clash between the US and Europe over 5G’s future development at The World Radiocommunication Conference 2019 (WRC-19) – taking place in Egypt from 28 October to 22 November 2019 – could risk $565bn of economic expansion globally over the next 15 years, warned the GSMA today.

This economic growth from next-generation 5G services depends on the availability of a specific strand of radio frequencies, known as ‘millimetre wave’ frequencies, which are set to be identified for use by mobile operators at WRC-19. However, efforts by Europe to constrain the use of these critical frequencies due to claims of potential interference with some space services has 5G’s future hanging in the balance.

“The stakes are high - a new generation of 5G services and the economic growth accompanying them will depend on the spectrum decisions taken at WRC-19,” said Brett Tarnutzer, Head of Spectrum, GSMA. “We are calling for Europe to join the US in taking a pro-5G stance at WRC-19 to protect its digital future. Some administrations are still determined to limit mobile use of airwaves that 5G requires to reach its full potential. This protectionist attitude will have consequences for our global economy if allowed to prevail.”

“Our focus is on ensuring that all regions are on board with the win-win resolution that will allow for robust 5G deployments globally while protecting satellite interests worldwide,” said Tom Power, Senior Vice President & General Counsel, CTIA. “Reports indicate that the fastest 5G peak speeds today are in the US, and that’s because the US was the first to deploy mmWave. The benefits of using this spectrum are clear but only through global harmonization at WRC-19 will all regions gain the greatest value.”

Benefits of mmWave spectrum

mmWave bands are critical to providing ultra-high speeds and ultra-high capacity for a wide range of consumer, business and government services that require almost instantaneous delivery of large amounts of data. This includes entertainment services such as downloading ultra-high definition movies in seconds, virtual and augmented reality applications, remote surgery with ‘haptic’ feedback, precise control of industrial devices and robots, and autonomous vehicles.

Three thousand delegates from over 190 nations will meet at WRC-19 to agree on how this spectrum may be used. Different countries may have different approaches and strategies, but WRC is the meeting point for all nations to maximize the potential for 5G within their borders by thinking globally. The process of harmonization at WRC-19 delivers global roaming and economies of scale for vendors and carriers, and that translates into lower costs, faster deployments and greater convenience for consumers.

Clash over airwaves at WRC-19

The build-up to WRC-19 is a four-year process and the use of mmWave spectrum has been the subject of intense technical study throughout. WRC-19 is the final decision after a lot of analysis and technical study.

Technical studies supported by the Americas, Africa and Arab states, have demonstrated that 5G using mmWave spectrum can co-exist safely and efficiently alongside weather-sensing services, commercial satellite services and others. These were conducted within the ITU, a UN agency. In the US, the FCC developed emission limits on 5G to protect weather sensors in nearby spectrum bands. Ahead of WRC-19, the FCC and the State Department also worked with regulators from other countries throughout the Americas, achieving consensus at the CITEL conference in Ottawa in August.

Despite this body of evidence, European countries are looking to limit the use of mmWave spectrum by setting protective technical conditions.

“It is important to follow studies which make realistic assumptions about how networks will function and make the best use of the spectrum for all,” added Brett Tarnutzer. This approach is being followed in the Americas, Africa and the Middle East but we need to find a global solution, including Europe. Large ‘guard bands’ will be needed – that is empty tranches of unused spectrum separating services - if we have technical limits which are too severe. This will restrict the economic benefit we can gain from finite spectrum resources and harm consumers and industry.”

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
For the GSMA
Gearóid Cashman
+44 79 7679 0169
gcashman@webershandwick.com

GSMA Press Office
pressoffice@gsma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye